Rebamipide in a Combination Therapy of Helicobacter pylori-Associated Gastroduodenal Ulcer: Systematized Published Data
Issues related to prevention and treatment of Helicobacter pylori-associated gastroduodenal ulcer still remain of high priority for clinicians. Here, systematized published data regarding results of experimental and clinical studies about usage of new gastroprotector drug rebamipide in patients with H. pylori-associated pathology are presented. Practicability of using rebamipide in a combination therapy of H. pylori-associated gastroduodenal ulcer is outlined, which is accounted for by increased efficacy of H. pylori eradication protocols as well as potentiation of mucosal repair processes in gastroduodenal area.